{"nctId":"NCT02535572","briefTitle":"Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment","startDateStruct":{"date":"2015-08"},"conditions":["Depression"],"count":48,"armGroups":[{"label":"FEAST","type":"EXPERIMENTAL","interventionNames":["Device: FEAST"]},{"label":"RUL UB","type":"ACTIVE_COMPARATOR","interventionNames":["Device: RUL UB"]}],"interventions":[{"name":"FEAST","otherNames":[]},{"name":"RUL UB","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Major Depressive Episode\n* Pretreatment Hamilton Depression Score \\>21\n* ECT indicated\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* History of schizophrenia, schizoaffective disorder, other functional psychosis, or rapid cycling bipolar disorder\n* History of central nervous system illness or insult other than conditions associated with psychotropic exposure (e.g., tardive dyskinesia)\n* Alcohol or substance abuse or dependence in the past year (DSM-V)\n* Secondary diagnosis of a delirium, dementia, or amnestic disorder (DSM-V), pregnancy, or epilepsy\n* Requires especially rapid antidepressant response due to suicidality, psychosis, inanition, psychosocial obligations, etc.\n* No anticonvulsant mood stabilizers (e.g., Depakote, Tegretol, Lamictal); No lithium; No psychostimulants (e.g., Ritalin, Adderall);\n\nAllowed medications during FEAST/ECT:\n\nAntidepressants, including buproprion Atypical antipsychotics; Hypnotics for sleep; Anxiolytics (limited to up to 3 mg equivalents/day lorazepam)\n\n* ECT in the past six months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Depressive Symptoms as Assessed by Hamilton Rating Scale for Depression","description":"The 24-item Hamilton Rating Scale for Depression has a range score of 0-7 (no depression) 7-17(mild depression) 17-24 (moderate depression) 25 and higher (severe depression). The Hamilton Rating Scale for Depression has a range of 0-72.\n\nLower score represents mild depression to no depression at all. A score of 21 or higher for clinical depression (inclusion criteria to participate in study).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.83","spread":"18.36"},{"groupId":"OG001","value":"61.81","spread":"20.80"}]}]}]},{"type":"PRIMARY","title":"Time to Return to Orientation","description":"Acute and subacute cognitive side effects following FEAST will be assessed with a brief neuropsychological battery. The primary acute measures will be the time to return of orientation following seizure induction. The neuropsychological measures will be compared in the patients treated with the FEAST methodology (under this IDE) and matched (but nonrandomized) patients who are treated with conventional ECT methods (also covered under this IDE).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.56","spread":"5.03"},{"groupId":"OG001","value":"8.79","spread":"5.83"}]}]}]},{"type":"PRIMARY","title":"Retrograde Amnesia for Autobiographical Information Using CUAMI-SF Consistency Scores","description":"Columbia University Autobiographical Memory Interview (CUAMI-SF) assesses the percent consistency in responses and has a maximum of 100%, with lower percentages representing increasing inconsistency. In this interview subjects receive points for each question they answer at Baseline and again at study follow-up, and are graded on the consistency of their answers.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.64","spread":"15.08"},{"groupId":"OG001","value":"64.66","spread":"9.83"}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events","description":"Safety will also be determined by examining the number and frequency of serious adverse advents and adverse events from the start of the study through the six month follow up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["headache","muscle ache","Nausea","prolonged seizure","postictal agitation),"]}}}